SOURCE: Implant Sciences

Implant Sciences

February 16, 2011 12:30 ET

Implant Sciences Retains Former Assistant Secretary of Defense Paul McHale

Company Seeks to Expand Presence in U.S. Market

WILMINGTON, MA--(Marketwire - February 16, 2011) - Implant Sciences Corporation (PINKSHEETS: IMSC) (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced the Company has retained the consulting services of former Assistant Secretary of Defense Paul McHale. Mr. McHale is the president of Civil Support International LLC, a consulting firm offering advisory services to government agencies and private contractors related to military sales, homeland defense, disaster preparedness and crisis response.

An internationally recognized expert in counterterrorism and homeland defense, Mr. McHale will help to identify new market opportunities for the sale of Implant Sciences' Quantum Sniffer™ explosives trace detection device to the U.S. government and foreign markets. Implant Sciences will build upon Mr. McHale's professional insight with the establishment of a dedicated U.S. government sales and marketing team. 

Mr. McHale served as the Assistant Secretary of Defense for Homeland Defense from 2003 to 2009. He also served as a member of the U.S. House of Representatives from Pennsylvania's 15th district between 1993 and 1999. While in Congress, Mr. McHale was an active member of the House Armed Services Committee. A retired colonel in the Marine Corps Reserve, Mr. McHale served in Operations Desert Shield and Desert Storm, and was deployed to Afghanistan in 2007. While in Afghanistan, he was a senior advisor to the Afghan National Police.

Mr. McHale commented, "Implant Sciences' Quantum Sniffer and its underlying technology are extremely effective in both foreign combat and homeland security applications. I am pleased to bring this technology to the attention of counterterrorism professionals and procurement officers around the world in order to save innocent lives, better secure our borders and protect our troops."

"We have had great success with sales of the Quantum Sniffer in international markets and believe that our technology provides just as much value to the security and defense markets in the U.S.," stated Glenn Bolduc, CEO of Implant Sciences. "We expect Mr. McHale to be a key advisor in identifying new operational applications and related sales opportunities. By building a U.S. government sales force, we hope to provide superior protection for Americans, while improving upon our sales channel growth and revenue momentum."

About the Quantum Sniffer QS-H150
The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Science's QS-H150 Portable Explosives Detectors has been Designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact